1-(2-(3-nitrophenoxy)ethyl)pyrrolidin-2-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(2-(3-nitrophenoxy)ethyl)pyrrolidin-2-one
• 英文别名: 1-[2-(3-Nitrophenoxy)ethyl]pyrrolidin-2-one
• 化学式: C₁₂H₁₄N₂O₄
• 分子量: 250.254
• InChiKey: HKHWPKMSBULVTN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  75.4
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-(2-(3-nitrophenoxy)ethyl)pyrrolidin-2-one 在 tin(II) chloride dihdyrate 作用下， 以 乙醇 为溶剂， 反应 3.0h， 以91%的产率得到1-(2-(3-aminophenoxy)ethyl)pyrrolidin-2-one
  参考文献：
  名称：

  Fine tuning of 4,6-bisphenyl-2-(3-alkoxyanilino)pyrimidine focusing on the activity-sensitive aminoalkoxy moiety for a therapeutically useful inhibitor of receptor for advanced glycation end products (RAGE)

  摘要：

  Through the fine tuning of the activity-sensitive aminoalkoxy moiety of 4,6-bisphenyl-2-(3-alkoxyanilino)pyrimidine as a novel inhibitor of the receptor for advanced glycation end products (RAGE), the tertiary amine was elucidated as an essential part associated with RAGE inhibition. On the basis of this finding, a 3-(N,N-dimethylamino)pyrrolidine analog 12o was identified as a therapeutically useful RAGE inhibitor with improved activity and solubility. Molecular modeling studies predicted that the improved inhibitory activity is induced by additional hydrogen bonds between the nitrogen atom of the pyrrolidine ring and Arg48 and by an interaction between the dimethylamino-substituent of the pyrrolidine moiety and a relatively hydrophobic groove in the RAGE binding site. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.12.003
• 作为产物：
  描述：

  N-羟乙基-2-吡咯烷酮 、 间硝基苯酚 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 以83%的产率得到1-(2-(3-nitrophenoxy)ethyl)pyrrolidin-2-one
  参考文献：
  名称：

  Fine tuning of 4,6-bisphenyl-2-(3-alkoxyanilino)pyrimidine focusing on the activity-sensitive aminoalkoxy moiety for a therapeutically useful inhibitor of receptor for advanced glycation end products (RAGE)

  摘要：

  Through the fine tuning of the activity-sensitive aminoalkoxy moiety of 4,6-bisphenyl-2-(3-alkoxyanilino)pyrimidine as a novel inhibitor of the receptor for advanced glycation end products (RAGE), the tertiary amine was elucidated as an essential part associated with RAGE inhibition. On the basis of this finding, a 3-(N,N-dimethylamino)pyrrolidine analog 12o was identified as a therapeutically useful RAGE inhibitor with improved activity and solubility. Molecular modeling studies predicted that the improved inhibitory activity is induced by additional hydrogen bonds between the nitrogen atom of the pyrrolidine ring and Arg48 and by an interaction between the dimethylamino-substituent of the pyrrolidine moiety and a relatively hydrophobic groove in the RAGE binding site. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.12.003

文献信息

• [EN] HETEROARYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROARYLE ET UTILISATIONS ASSOCIÉES
  申请人：AVILA THERAPEUTICS INC

  公开号：WO2011090760A1

  公开（公告）日：2011-07-28

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了化合物，其药物学上可接受的组成物以及使用它们的方法。
• HETEROARYL COMPOUNDS AND USES THEREOF
  申请人：Singh Juswinder

  公开号：US20100249092A1

  公开（公告）日：2010-09-30

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供化合物及其药学上可接受的组成物，以及使用它们的方法。
• Heteroaryl Compounds and Uses Thereof
  申请人：Singh Juswinder

  公开号：US20100029610A1

  公开（公告）日：2010-02-04

  The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了化合物、其药学上可接受的组合物以及使用它们的方法。
• 2,4-disubstituted pyrimidines useful as kinase inhibitors
  申请人：Celgene CAR LLC

  公开号：US10010548B2

  公开（公告）日：2018-07-03

  The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.

  本发明提供了可用作激酶抑制剂的 2,4-二取代嘧啶化合物、其药学上可接受的组合物以及使用方法。
• Substituted 2,4-diaminopyrimidines as kinase inhibitors
  申请人：Celgene CAR LLC

  公开号：US10828300B2

  公开（公告）日：2020-11-10

  The present invention provides 2,4-diaminopyrimidines, and/or pharmaceutically acceptable compositions thereof, as kinase inhibitors.

  本发明提供了作为激酶抑制剂的 2,4-二氨基嘧啶和/或其药学上可接受的组合物。